Optibrium Appoints Dr Nathan Brown as Director of Science
Newly created role underscores commitment to customer-driven research and scientific excellence CAMBRIDGE, UK, 13 January 2026 – Optibrium, a leading developer of software and AI…
Optibrium Delivers Real-Time Collaboration in its Comprehensive Molecular Design Platform with StarDrop 8
Latest release accelerates hit-to-candidate progression by keeping teams aligned, eliminating inefficiencies and enabling better prioritisation decisions CAMBRIDGE, UK, 04 November…
Optibrium secures multi-million-pound financing package from Shawbrook to accelerate business growth
Proceeds will accelerate Optibrium’s product development and expand the global reach of its computational chemistry and AI-driven discovery technology. CAMBRIDGE,…
Optibrium partners with TalTech on EU-funded PhD programme to advance sustainable drug discovery
The research will focus on developing faster and more accurate methods for predicting drug metabolism. CAMBRIDGE, UK, 02 July 2025…
Optibrium Widens Access to Industry-Leading Docking Method
New PyMOL interface extends access to Optibrium’s structure-based design method Surflex-Dock CAMBRIDGE, UK, 04 February 2025 – Optibrium, a leading…
Optibrium demonstrates superior molecular docking method for small molecules and macrocycles
CAMBRIDGE, UK, 22 October 2024 – Optibrium, a leading developer of software and AI solutions for molecular design today announced…
26th North American ISSX and JSSX Meeting
The joint ISSX/JSSX meeting is for researchers looking to gain a deeper understanding of drug metabolism and pharmacokinetics.
7th RSC-BMCS AI in chemistry conference
The Chemical Information & Computer Applications Group (CICAG) and Biological & Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry are once again organising a conference to present the current advances in AI and machine learning in Chemistry.
Where can you catch up with Optibrium over the summer?
Join Optibrium during a full program of summer events showcasing our Cerella platform.
Meet with us at ACS Fall 2024
Join Daniel Barr to hear more about how deep learning imputation prioritises the most relevant data, accounts for uncertainty, and guides experiment selection to bring additional value to small molecule discovery.
38th ACS National Medicinal Chemistry Symposium
Join Optibrium’s Chris Khoury at the 38th NMCS meeting in Seattle, 23-26 June
Optibrium partners with FMC Corporation to transform agrochemical discovery
CAMBRIDGE, UK and CAMBRIDGE, US 14 May 2024 – Optibrium, a leading developer of software and AI solutions for drug…
Optibrium’s quantum mechanics and machine learning methods predict routes of drug metabolism
Peer-reviewed study published in Xenobiotica describes an innovative new method that predicts the routes and products of Phase I and II metabolism with high sensitivity and greater precision than
other approaches
Optibrium expands operations in North America for AI and computational drug discovery technologies
Establishment of Optibrium Inc. bolsters ongoing strategic Company growth and strenghtens direct US customer support. Dr Tamsin Mansley promoted to President of Optibrium Inc. to lead growing US-based team and business operations.
Optibrium releases powerful metabolism prediction capability in next generation StarDrop software
Backed by six years’ research, the new StarDrop Metabolism module combines quantum mechanics and machine learning to better predict the metabolic fate of drug candidates.
Optibrium strengthens global AI drug discovery software operations with three key appointments
Michelle Harrison appointed as Head of Strategic Marketing; Chris Khoury and Imran Ghauri join to boost Optibrium’s business development team. UK and US-based appointments with proven AI and life science expertise will support the next phase of commercial growth for Optibrium’s computational drug discovery technologies.
Optibrium appoints Ian Smith as Chief Technology Officer
New role will lead technology development as the Company continues to scale team and global business operations. Appointment of former Merck, Sharp and Dohme (MSD) Director of R&D Analytics supports continued innovation of Optibrium’s AI drug discovery software.
Optibrium receives further investment from Kester Capital
Second round of funding from existing investors will further drive company expansion and commercial growth of its AI-enabled drug discovery technology.
Models for success: improving drug metabolism prediction
Out now in Drug Target Review, Optibrium’s Director of Computational Chemistry, Dr Peter Hunt discusses why early in silico metabolism prediction is crucial…
